130 related articles for article (PubMed ID: 17618256)
1. Straight talk from... Bruce Psaty. Interviewed by Emma Marris.
Psaty B
Nat Med; 2007 Jul; 13(7):767. PubMed ID: 17618256
[No Abstract] [Full Text] [Related]
2. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
3. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
4. Rosiglitazone, marketing, and medical science.
Moynihan R
BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
[No Abstract] [Full Text] [Related]
5. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
6. The rosigliazone meta-analysis: lessons for the future.
Shuster JJ; Schatz DA
Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
[No Abstract] [Full Text] [Related]
7. Drug safety. Heart attack risk overshadows a popular diabetes therapy.
Couzin J
Science; 2007 Jun; 316(5831):1550-1. PubMed ID: 17569830
[No Abstract] [Full Text] [Related]
8. Analytical issues regarding rosiglitazone meta-analysis.
Claggett B; Wei LJ
Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
[No Abstract] [Full Text] [Related]
9. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
10. The rosiglitazone meta-analysis.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
[No Abstract] [Full Text] [Related]
11. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
12. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
13. Faster publication isn't always better.
Fuster V; Farkouh ME
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
[No Abstract] [Full Text] [Related]
14. Thiazolidinediones, deadly sins, surrogates, and elephants.
Cleland JG; Atkin SL
Lancet; 2007 Sep; 370(9593):1103-4. PubMed ID: 17905146
[No Abstract] [Full Text] [Related]
15. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
16. Avandia in perspective.
Comarow A
US News World Rep; 2007 Oct; 143(11):71. PubMed ID: 17957906
[No Abstract] [Full Text] [Related]
17. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
18. Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?
Bilous RW
Diabet Med; 2007 Sep; 24(9):931-3. PubMed ID: 17725705
[No Abstract] [Full Text] [Related]
19. Rosiglitazone and implications for pharmacovigilance.
Kazi D
BMJ; 2007 Jun; 334(7606):1233-4. PubMed ID: 17569897
[TBL] [Abstract][Full Text] [Related]
20. Avandia outcome may signal change in epidemiologists' sway.
Wadman M
Nat Med; 2010 Jun; 16(6):614. PubMed ID: 20526293
[No Abstract] [Full Text] [Related]
[Next] [New Search]
